Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients.

Liu X, Xu X, Lu ZJ, Shih YT

DOI: 10.1001/jamaoncol.2026.3128
Published: 2026 Aug 27
Container: JAMA oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2026.3128,
  title = {Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients.},
  author = {Liu X and Xu X and Lu ZJ and Shih YT},
  year = {2026},
  journal = {JAMA oncology},
  doi = {10.1001/jamaoncol.2026.3128},
  url = {https://doi.org/10.1001/jamaoncol.2026.3128}
}

RIS

TY  - JOUR
TI  - Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients.
AU  - Liu X
AU  - Xu X
AU  - Lu ZJ
AU  - Shih YT
PY  - 2026
JO  - JAMA oncology
DO  - 10.1001/jamaoncol.2026.3128
UR  - https://doi.org/10.1001/jamaoncol.2026.3128
ER  -

APA

X, L., X, X., ZJ, L., & YT, S. (2026). Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients.. JAMA oncology. https://doi.org/10.1001/jamaoncol.2026.3128

Source records

pubmed · retrieved 2026-09-26T05:21:51.909Z